PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00130897
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Phase 3
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: Investigator's choice
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 169
- Registration Number
- NCT00117598
- Locations
- π¬π§
Pfizer Investigational Site, Sutton, Surrey, United Kingdom
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00113529
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00113516
- Locations
- π«π·
Pfizer Investigational Site, Villejuif, France
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
Phase 3
Terminated
- Conditions
- BacteremiaGram-Positive Bacterial Infections
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00108433
- Locations
- πΈπ°
Pfizer Investigational Site, Nitra, Slovakia
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00106639
- Locations
- πΊπΈ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT00106353
- Locations
- π·πΊ
Pfizer Investigational Site, Saint Petersburg, Russian Federation
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Phase 2
Terminated
- Conditions
- Colorectal NeoplasmsLiver Neoplasms
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT00106054
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00102895
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Phase 3
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: Modified Bolus 5-FU/LV with IrinotecanDrug: FOLFIRI + bevacizumabDrug: miFL + bevacizumabDrug: Infusional 5-FU/LV with Irinotecan
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 547
- Registration Number
- NCT00101686
- Locations
- π³πΏ
Pfizer Investigational Site, Wellington, New Zealand
Β© Copyright 2025. All Rights Reserved by MedPath